Profile data is unavailable for this security.
About the company
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
- Revenue in USD (TTM)5.37m
- Net income in USD-64.02m
- Incorporated2006
- Employees95.00
- LocationOcugen Inc11 GREAT VALLEY PARKWAYMALVERN 19355United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://ocugen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences Inc | 37.19m | -38.55m | 421.68m | 73.00 | -- | 2.31 | -- | 11.34 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| PepGen Inc | 0.00 | -93.56m | 442.74m | 81.00 | -- | 2.71 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 444.22m | 27.00 | -- | 8.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 447.98m | 30.00 | -- | 3.65 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Verastem Inc | 13.38m | -241.11m | 449.04m | 78.00 | -- | -- | -- | 33.56 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 460.55m | 72.00 | -- | 2.87 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Ocugen Inc | 5.37m | -64.02m | 462.32m | 95.00 | -- | 124.65 | -- | 86.09 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 472.84m | 52.00 | -- | 1.25 | -- | 168.93 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 473.38m | 869.00 | -- | 1.86 | 98.87 | 1.02 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 476.92m | 227.00 | -- | 1.19 | -- | 3,974.36 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 482.26m | 100.00 | -- | 2.21 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 482.32m | 163.00 | -- | 1.64 | -- | 40.92 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 494.27m | 263.00 | -- | -- | -- | 6.57 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 505.13m | 82.00 | 10.74 | 0.9575 | 7.67 | 2.05 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
Data as of Feb 17 2026. Currency figures normalised to Ocugen Inc's reporting currency: US Dollar USD
18.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 28 Nov 2025 | 20.00m | 6.10% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 14.49m | 4.42% |
| UBS Securities LLCas of 31 Dec 2025 | 4.68m | 1.43% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.30m | 1.31% |
| Millennium Management LLCas of 30 Sep 2025 | 4.16m | 1.27% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.98m | 1.21% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.82m | 1.17% |
| Marshall Wace LLPas of 31 Dec 2025 | 2.53m | 0.77% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 2.22m | 0.68% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 1.87m | 0.57% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
